Table 2 Summary of trial design
From: Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis
Trial | Patient populationa | Number of centres | Surfactant (doseb) | Control | Primary outcome | Duration of follow-up | Funding source |
|---|---|---|---|---|---|---|---|
Luchetti, 1998 | Severe bronchiolitis | Unclear, probably 1 | Poractant – porcine (50 mg/kg single dose) | None | Unclear | PICU discharge | Not reported |
Willson, 1999 | ARDS/ALI | 8 | Calfactant – bovine (2,800 mg/m2 every 12 hours for 1–4 doses) | None | Mortality | Hospital discharge | Partial support by surfactant manufacturer |
Tibby, 2000 | RSV-induced respiratory failure | Unclear, probably 1 | Beractant – modified bovine (100 mg/kg every 24 hours for 2 doses) | Air placebo | Indices of gas exchange | Hospital discharge | Not reported |
Luchetti, 2002 | RSV-induced respiratory failure | 6 | Poractant – porcine (50 mg/kg dose every 24 hours for 1–2 doses) | Sedation and manual ventilation | Vent days and PICU stay | PICU discharge | Not reported |
Moller, 2003 | ARDS | 19 | Bovactant – bovine (100 mg/kg, 1–2 doses within 48 hours) | None | Change in PaO2/FiO2 at 48 hours | 30 days | Surfactant manufacturer |
Willson, 2005 | ARDS/ALI | 21 | Calfactant – bovine (2,800 mg/m2 – if <10 kg, 105 mg/kg – every 12 hours for 1–2 doses) | Air placebo | Ventilator-free days at day 28 | Hospital discharge | Surfactant manufacturer |